Amplitude Launches the Industry’s First Digital Optimization Ecosystem
Amplitude, the Digital Optimization System, today announced the Amplitude Partner Ecosystem, an industry-first program which brings together more than 40 founding partners to help customers accelerate and optimize digital transformation and product innovation strategies.
“Today, businesses have two options: Become a digital disruptor or be digitally disrupted. Digital products are now at the center of the innovation agenda, requiring new approaches and solutions to optimize and accelerate value creation,” said Lisa Hopkins, VP of Partnerships at Amplitude. “Our ecosystem brings together a network of partners at the forefront of digital disruption to make it easy for every business to build the right digital strategies and transform experiences. We look forward to working with and expanding our partner network to help our customers on their digital journeys.”
By joining the Amplitude Partner Ecosystem, partners gain access to a range of resources and benefits, including Amplitude technical experts, training and certification programs, and joint sales and marketing opportunities, making it easier than ever to build and deliver innovative solutions to customer problems and cultivate new business opportunities. More than 40 ecosystem partners have joined as founding members, with the intent to add new partners on an ongoing basis. Two categories of partners include:
Solution partners: Amplitude partners with a network of global systems integrators, consultancies and digital agencies to provide business transformation strategy, best practices and technology implementation support. Founding member solution partners include Accenture, Converteo, Phiture and ConsultMyApp.
Technology integrations: The ecosystem includes technology integrations across 16 software categories to build and deliver end-to-end customer engagement processes. A sample of founding member integration partners include:
- Marketing Automation: Integrations with marketing technologies, including Braze, Airship and Iterable, leverage Amplitude behavioral data to help marketing teams run more targeted, personalized campaigns and understand how campaign engagement impacts business metrics such as retention and loyalty.
- Attribution: Amplitude integrates with attribution technologies, including Branch, AppsFlyer and Singular, to combine attribution data with behavioral data for more granular campaign analysis and to optimize marketing return on investment.
- Customer Data Platform (CDP): Amplitude integrates with CDPs, including Segment and mParticle, to help product and analytics teams more easily query the data in the CDP to gain faster access to insights.
"We are very happy to support Amplitude’s customers to bring data and behavioural analytics at the heart of their digital product strategy thanks to our team of certified consultants,” said Pierre-Adrien Lair, Lead Analytics at Converteo.
"Amplitude is a fantastic partner and a critical element of the growth ecosystem; they have a fantastic product and the team here at Phiture know it intimately. Phiture helps app publishers to leverage Amplitude to the fullest to derive actionable insight and measure the impact of growth initiatives against the KPIs that matter most. Phiture brings expertise in Data Governance, Product Intelligence and Growth Marketing, while Amplitude brings a best-in-class Insights Solution with excellent integrations to other tools in the marketing stack and keeps pace with the ever-evolving needs of the marketplace,” said Andy Carvell, Partner and CoFounder, Phiture Mobile Growth Consultancy.
Today, Amplitude also unveiled the industry’s first Digital Optimization System, a unified system to help businesses connect digital product innovation to business outcomes and answer the strategic question: “How do our digital products drive our business?”
To learn more about the Amplitude Digital Optimization Ecosystem and joining the Amplitude Partner Program, visit: amplitude.com/partners.
About Amplitude
Amplitude is the Digital Optimization System. Powered by the proprietary Amplitude Behavioral Graph, the Digital Optimization System enables organizations to see and predict which combination of features and actions translate to business outcomes - from loyalty to lifetime value - and intelligently adapt each experience in real-time based on these insights. Amplitude is the brain behind more than 45,000 digital products at over 1,000 enterprise customers and 23 of the Fortune 100, helping them innovate faster and smarter by answering the strategic question: “How do our digital products drive our business?” Learn more at www.amplitude.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005490/en/
Contact information
Clarity PR for Amplitude
Kerry Rothery
Amplitude@clarity.pr
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom